Doliver Advisors’s Novo Nordisk NVO Stock Holding History

Doliver Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$803K	Buy	16,741 +3,415	+26%	+$147K	0.18%	94
2026 Q1	$490K	Buy	13,326 +1,342	+11%	+$63.6K	0.11%	116
2025 Q4	$610K	Sell	11,984 -977	-8%	-$50K	0.15%	107
2025 Q3	$719K	Buy	12,961 +3,049	+31%	+$178K	0.19%	94
2025 Q2	$684K	Sell	9,912 -5,778	-37%	-$393K	0.19%	90
2025 Q1	$1.09M	Sell	15,690 -535	-3%	-$44.2K	0.31%	57
2024 Q4	$1.4M	Buy	16,225 +5,721	+54%	+$619K	0.39%	43
2024 Q3	$1.25M	Sell	10,504 -188	-2%	-$25.1K	0.34%	52
2024 Q2	$1.53M	Sell	10,692 -81	-0.8%	-$10.7K	0.43%	39
2024 Q1	$1.38M	Buy	+10,773	New	+$1.28M	0.39%	46

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

OFA

Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Doliver Advisors's NVO Position: Q2 2026 in Review

Doliver Advisors increased its Novo Nordisk (NVO) stake by 26% in Q2 2026, buying an estimated $147K and bringing the position to 16,741 shares worth $803K. The position accounts for 0.18% of the portfolio, ranked #94.

Doliver Advisors first reported a position in NVO in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.53M in Q2 2024. 387 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Doliver Advisors held 16,741 shares of Novo Nordisk worth $803K as of Q2 2026.
Doliver Advisors bought 3,415 Novo Nordisk shares in Q2 2026, an estimated $147K.
Novo Nordisk made up 0.18% of Doliver Advisors's portfolio in Q2 2026, its #94 holding.
Doliver Advisors first reported a position in Novo Nordisk in Q1 2024 and has held it in 10 quarters since.
Doliver Advisors's Novo Nordisk position peaked at $1.53M in Q2 2024.
387 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.